Program Overview

1. What percentage of the drugs in your company’s portfolio have one or both of the following programs?
  % Disease Management   
  % Patient Adherence   

2. In your estimate, what percentage of an average drug’s sales are forgone because of adherence issues?
  %

3. At what point in a drug’s lifecycle did/do you assemble a team focused on developing a special adherence/disease management program?
Pre-Clinical
Phase I
Phase II
Phase III
Registration & Launch
First year

4. Who is responsible for spearheading adherence/disease management program(s) within each brand team?

5. Who leads the program’s development/maintenance?
  Brand Team
  Marketing
  Other: please specify
  Other: please specify

6. What other functions are involved in a program’s development/maintenance (please check all that apply)?
  Brand Team
  Marketing
  Medical Affairs
  Market Research
  Reimbursement
  Regulatory
  Patient Relations
  Other - please specify:
  Other - please specify:

7. What is the average team size involved with launching/maintaining a disease management/patient adherence program?
Launching a program:  FTEs
Maintaining a program:  FTEs

Outsourcing/Challenges

8. Does your company outsource any of the following patient adherence/disease management activities (please check all that apply):
  Market Research
  Concept Development
  Technology Platforms
  Call Centers
  Communications with Program Users
  Material Development
  Other - please specify:
  Other - please specify:

9. Does your company have any outcome measurements in place to determine ROI of your programs?
  Yes
  No

10. Does your company have non-branded disease awareness campaigns?
  Yes
  No

11. Please rate the impact of the following challenges on program development (1 = not very challenging and 5 = very challenging).
Please select: 1 2 3 4 5   Senior management buy-in
Please select: 1 2 3 4 5   Attaining sufficient resource levels
Please select: 1 2 3 4 5   Technology barriers
Please select: 1 2 3 4 5   Inexperience in program development
Please select: 1 2 3 4 5   Understanding the audience
Please select: 1 2 3 4 5   Effectively communicating with end users (use of feedback loops)
Please select: 1 2 3 4 5   Persuading stakeholders of the program's value
Please select: 1 2 3 4 5   Demonstrating ROI
Please select: 1 2 3 4 5   Following regulations
Please select: 1 2 3 4 5   Integrating marketing communications
Please select: 1 2 3 4 5   Providing customized messages
Please select: 1 2 3 4 5   Overcoming barriers of trust
Please select: 1 2 3 4 5   Other - please specify:
Please select: 1 2 3 4 5   Other - please specify:

Program Specifics

For the following section, please draw on the specific experience of one patient adherence/disease management program.

12. Optional: Please identify which program you will be referring to.  This information will remain confidential – we will simply use it to better understand your survey responses.

13. What percentage of the product’s overall marketing budget is spent on this adherence/disease management program?
%

14. Is this program designed for acute or chronic conditions?
Acute
Chronic
Other - please specify:

15a. If the program is supporting a specific brand, what is that brand’s expected peak annual sales?
$

15b. If the program is non-branded, what is the therapeutic area’s annual sales at your company?
$

16. If the program supports a specific brand, what percentage of the drug’s patients does your company feel is compliant at each stage below (if applicable)?

17. In your estimate, how much does it cost this product to:
$   Attain a new patient
$   Retain an existing patient

18. If the program supports a specific brand, at what point in the drug’s lifecycle did you do the following activities?

Budget

19. How long, in terms of months, did it take to develop the program – from project conception to implementation?
  months

20a. Did you run a pilot for this program?
  Yes
  No

20b. If so, how long did it last?
months

21. From concept to implementation, what do you estimate was/will be your company’s investment in developing the program?
$

22. What percentage of the program’s development budget was outsourced?
  %

23. Of the total investment in the program, what percentage do you think went to the following categories?

24. What is/will be the average annual investment your company will need to make in order to maintain the program?
$

25. From where does your program receive its budget (please check all that apply)?
  Marketing
  Corporate
  Brand Team
  Therapeutic Area/Business Unit
  Global Marketing Organization
  Patient Relations
  Advocacy
  Medical Affairs
  Other - please specify:
  Other - please specify:

26. How many individuals, measured in full-time equivalents (FTEs) worked on the program?

27. In your estimation, how long did the following steps take your company?

Media

28. What media channels did/do you leverage in this program (please check all that apply)?
  Internet
  Email
  Print
  TV
  Telephone
  Text Messaging
  PDA
  Medical Devices
  Patient Loyalty Cards (Pharmacy)
  Personal Contact (ex. Support Groups)
  Other - please specify:
  Other - please specify:

29. Do you involve healthcare professionals in your communications? (e.g. nurse-led call centers, pharmacy involvement)
  Yes
  No

30. Is this program used on a global scale?
  Yes
  No

General Media Effectiveness

31. Please rank all media below.

What is your perception of the effectiveness of each of the following media platforms, in terms of communicating with audiences?  (1 being not that effective and 5 being very effective).

 
Please select: 1 2 3 4 5   Internet
Please select: 1 2 3 4 5   Email
Please select: 1 2 3 4 5   Print
Please select: 1 2 3 4 5   TV
Please select: 1 2 3 4 5   Telephone
Please select: 1 2 3 4 5   Text Messaging
Please select: 1 2 3 4 5   PDA
Please select: 1 2 3 4 5   Medical Devices
Please select: 1 2 3 4 5   Patient Loyalty Cards (Pharmacy)
Please select: 1 2 3 4 5   Personal Contact (ex. Support Groups)
Please select: 1 2 3 4 5   Other - please specify:
Please select: 1 2 3 4 5   Other - please specify: